This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Novartis AG

Drug Names(s): Vildagliptin/LAF237/Galvus + metformin, Icandra, Galvusmet, Zomarist, Equmet (Japan)

Description: Eucreas is a combination of Galvus with metformin, which acts primarily by reducing the amount of glucose produced by the liver. Galvus, meanwhile, is an inhibitor of di-peptidyl peptidase-IV (DPP-IV), an enzyme that breaks down glucagon-like peptide-1 (GLP-1). GLP-1 binds to receptors on pancreatic beta cells stimulating the release of the hormone insulin. GLP-1 also reduces the secretion of glucagon, a hormone produced by the pancreas that stimulates the liver to convert glycogen to glucose thus increasing blood sugar levels. By delaying the degradation of GLP-1, DPP-IV inhibitors extends the action of insulin while also suppressing the release of glucagon.

BioMedTracker groups Galvus and Eucreas revenue together.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

In June 2004, OSI acquired a portfolio of medical use patents relating to DPIV from Probiodrug. This portfolio contains a number of patent families comprising issued and pending patents and patent applications with claims relating to the use of DPIV inhibitors for the treatment of diabetes and related indications. OSI also licensed sub-licensable rights to patents and patent applications claiming combinations of DPIV inhibitors with other oral anti-diabetic drugs such as metformin. Its rights to this patent estate provide it with a source of upfront payments, and milestone and royalty revenue through the issuance of non-exclusive licenses to the patent estate. Novartis has taken a license to this patent estate and OSI is entitled to royalties from sales of Galvus and Eucreas.

UCB and Novartis
In August 2009, UCB and Novartis announced that they entered into a licensing agreement for cardiovascular and diabetes...See full deal structure in Biomedtracker

Partners: Royalty Pharma AG UCB SA

Eucreas News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug